NEWS & EVENTS

Catalent today announced that it has begun construction of a $20 million expansion project at its clinical supply facility in Schorndorf, Germany.

The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the adoption of advanced drug delivery technologies, announces that it will hold a symposium in affiliation with Johnson & Johnson Innovation – JLABS (JLABS).

The launch of the ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials.

Under its terms, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.

Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.

Catalent today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal’s pipeline.

Catalent today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.

Krishnan will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to drive sustainable execution excellence enabling growth.

Vice President of Business Transformation Matt Blume, will host a panel session at the upcoming Bio Supply Management Alliance Conference, to be held at the Crowne Plaza Suites Hotel, Foster City, California, on March 8 – 9, 2023.